Therapy News and Research

RSS

Current stem cell applications to be discussed at NJIT

Stem cell researcher Treena Livingston Arinzeh will discuss current stem cell applications at NJIT, including the regeneration of bone and cartilage for bone fracture and osteoarthritis treatments, spinal cord repair, and liver regeneration at NJIT's first Research Caf.

25 Sep 2009

Non-accredited education programs for people with chronic disabilities

iMedicor (VMCI.OB) formerly Vemics, Inc. and EP Global Communications (EPGL.OB) have announced the renewal of their strategic alliance agreement to produce Continuing Medical Education (CME) and non-accredited education programs for people with special needs and life long chronic disabilities. iMedicor/Vemics and EP Global Communications have worked together for a number of years and this relationship has generated substantial revenue for both companies and has provided a valuable service to the community they serve.

25 Sep 2009

Results from COGENT clinical trial presented at TCT symposium

Results from a late breaking clinical trial called COGENT demonstrate that the combination of giving patients clopidogrel, a blood thinner commonly prescribed to patients with cardiovascular disease, and stomach medicines such as omeprazole, known as proton pump inhibitors (PPIs), did not lead to adverse events, as some prior studies had suggested.

25 Sep 2009

Prevention and cure of Alzheimer's disease important to Americans

A new voter survey sponsored by the ACT-AD Coalition (Accelerate Cure/Treatments for Alzheimer's Disease) finds that three-quarters of Americans nationwide and across party lines say it is personally important to them to find a cure or to prevent Alzheimer's disease, while a similar proportion of the national electorate say they look to Congress to make it "a national priority" to speed up the Food and Drug Administration's (FDA) review process in specific ways for therapies that slow, halt or reverse the disease.

25 Sep 2009

PROSPECT clinical trial results announced

Abbott today announced primary results from its groundbreaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) clinical trial.

25 Sep 2009

Senators urge the CMS to spare funding cuts for radiation oncology services

Cancer physicians and cancer care advocates applauded a bipartisan letter led by Senators Richard Burr (R-NC) and Blanche Lincoln (D-AR) sent to Health and Human Services Secretary Kathleen Sebelius yesterday urging that the Centers for Medicare and Medicaid Services (CMS) spare life-saving radiation oncology services from a major Medicare funding cut proposed for diagnostic imaging services. The 32 Senators signing the letter stated their unanimous concern that these funding cuts could force freestanding and community-based cancer centers to shut down, thereby limiting access to care for seniors - particularly in rural areas.

25 Sep 2009

Phase III clinical trial of investigational HIV vaccine regimen complete

Global Solutions for Infectious Diseases (“GSID”) announced today that a Phase III clinical trial of an investigational HIV vaccine regimen has been shown to be safe and modestly effective in preventing HIV infection. The double-blind, placebo controlled study was conducted in Thailand among more than 16,000 volunteers.

25 Sep 2009

Clinic owner and operator admit to participating in a conspiracy to defraud the Medicare program

Clinic owners and operators Jose Martinez and Denisse Martinez pleaded guilty today in U.S. District Court in Detroit to participating in a conspiracy to defraud the Medicare program, Assistant Attorney General Lanny A. Breuer of the Criminal Division, U.S. Attorney Terrence Berg of the Eastern District of Michigan and Daniel R. Levinson, Inspector General of the Department of Health & Human Services (HHS) announced.

25 Sep 2009

Tooth cell banking for the treatment of future diseases

Pioneered by BioEDEN, tooth cell banking is a safe, natural and wholly non-invasive method of collecting and preserving precious stem cells which could hold the key to children's health.

25 Sep 2009

NTMs: Rising cause of severe lung diseases

Nontuberculous mycobacteria (NTM) are environmental organisms found in both water and soil that can cause severe pulmonary (lung) disease in humans. Pulmonary NTM is on the rise in the United States, according to a large study of people hospitalized with the condition.

25 Sep 2009

Multi-modality imaging to identify plaque

Late-breaking results from the PROSPECT clinical trial shed new light on the types of vulnerable plaque that are most likely to cause sudden, unexpected adverse cardiac events, and on the ability to identify them through imaging techniques before they occur.

25 Sep 2009

Contribution of psychological characteristics to weight loss

Being too optimistic could harm weight loss efforts. Research published in BioMed Central's open access journal, BioPsychoSocial Medicine, reveals the psychological characteristics that may contribute to weight loss.

25 Sep 2009

CTRC commences patient enrolment in Phase 2 clinical trial of REOLYSIN for metastatic melanoma

Oncolytics Biotech Inc. announced today that the Cancer Therapy Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with metastatic melanoma.

24 Sep 2009

Spherix's Annual Meeting of Shareholders to be held on November 17

Spherix Incorporated, an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its Annual Meeting of Shareholders will be held on November 17, 2009, at 9:00 a.m. Eastern time, at the Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, Maryland 20817.

24 Sep 2009

Everolimus-eluting stent efficient in treating native coronary artery lesions

Late-breaking data from SPIRIT IV, a large-scale multi-center study of nearly 4,000 patients in the U.S., shows that an everolimus-eluting stent demonstrated enhanced safety and efficacy in the treatment of de novo native coronary artery lesions when compared to a paclitaxel-eluting stent, and showed that "low late loss" may be achieved with drug-eluting stents without sacrificing safety.

24 Sep 2009

Clinical trial comparing Boston Scientific's coronary stent systems

Boston Scientific Corporation today welcomed one-year data from the SPIRIT IV clinical trial comparing the XIENCE V((R)) (PROMUS((R))) Everolimus-Eluting Coronary Stent System to the TAXUS((R)) Express2(TM) Paclitaxel-Eluting Coronary Stent System. The results support the benefits of paclitaxel-eluting stents in diabetic patients. The trial enrolled 3,690 patients, including 1,140 diabetics, the largest diabetic subset ever studied in a drug-eluting stent clinical trial.

24 Sep 2009

Octapharma AG submits Biological License Application for its octagam(R) 10% to FDA

Octapharma AG recently submitted its Biological License Application for octagam(R) 10% (human normal intravenous immunoglobulin, liquid) to the U.S. Food and Drug Administration (FDA) with the goal of expanding the biopharmaceutical company's U.S. immune globulin therapy portfolio by early 2010. The application was submitted for the treatment of Idiopathic Thrombocytopenic Purpura (ITP), a blood-clotting disorder that can result in excessive bruising and bleeding.

24 Sep 2009

HSA: Cutting autism support by $3 million is not good for kids

"Government spin won't help autistic children and their families," HSA President Reid Johnson said today in response to a massive government cut in support for autistic children across British Columbia.

24 Sep 2009

Research study links cancer to excess body weight

At least 124,000 new cancers in 2008 in Europe may have been caused by excess body weight, according to estimates from a new modelling study. The proportion of cases of new cancers attributable to a body mass index of 25kg/m2 or more were highest among women and in central European countries such as the Czech Republic, Latvia, Slovenia and Bulgaria.

From The University of Manchester 24 Sep 2009

Scientist reveals that selecting optimal radiation dosage for a patient is possible

An international group of scientists has taken the first step on the road to targeting radiotherapy dosage to individual patients by means of their genetic characteristics, a radiation oncologist told Europe's largest cancer congress, ECCO 15 - ESMO 34, in Berlin today (Thursday September 24). Professor Dirk de Ruysscher, from Maastricht University Medical Centre, Maastricht, The Netherlands, said that his team's work might provide the basis for personalised radiotherapy in which, with a simple blood test, doctors may be able to select the optimal radiation dose for a particular patient.

24 Sep 2009